Refining prognosis in early-stage colorectal cancer: one or multiple genes at a time?

Based on recent estimates, colon cancer remains the third most common newly diagnosed cancer type among both men and women in the United States [1]. At the time of curative surgical resection, stage II (node-negative) and stage III (node-positive) account for approximately 25% and 35% of new cases, respectively [2]. However, while multiple lines of evidence support the benefit of adjuvant systemic therapy in stage III disease, its exact role in stage II disease continues to be the subject of lively debate and active investigation [3].

http://ift.tt/2hmIacw